Clinical Trial Update: Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of VIP236 in patients with advanced cancer has completed; the update highlights safety, tolerability, and dose-ranging observation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• VIP236

Snippet

Sponsor: Vincerx Pharma, Inc. | Conditions: Neoplasms | Phase 1 | Status: COMPLETED